Jasper Therapeutics, Inc. Common Stock (JSPR)
Jasper Therapeutics, Inc. (JSPR) is a biotechnology company focused on developing therapies for hematopoietic stem cell transplantation. The company's primary goal is to improve conditioning regimens and expand treatment options for patients with blood disorders, including sickle cell disease, thalassemia, and certain malignancies. Jasper applies its proprietary technologies to create targeted conditioning agents and stem cell therapies to enhance transplant safety and efficacy.
Company News
Rosen Law Firm alerts Jasper Therapeutics investors about a securities class action lawsuit alleging false statements regarding manufacturing controls and product prospects during the period of November 30, 2023 to July 3, 2025.
Jasper Therapeutics reported a net loss of $1.74 per share in Q2 2025, with no revenue generated. The company is focusing exclusively on briquilimab, a monoclonal antibody for mast cell-driven diseases, while implementing significant cost-cutting measures.
Jasper Therapeutics (JSPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Although U.S. stocks closed mixed on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for mak...
Penny stocks to buy according to analysts in 2023 The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 952% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.